Phase II clinical trial testing the safety of a humanised monoclonal antibody anti-CD20 in patients with heart failure with reduced ejection fraction, ICFEr-RITU2: study protocol.
Luis Sánchez-TrujilloCarlos Jerjes-SanchezDavid RodriguezJathniel PanneflekClaudia Ortiz-LedesmaGerardo J García-RivasGuillermo Torre-AmionePublished in: BMJ open (2019)
The trial was approved by the IRB (CONBIOÉTICA-19-CEI-011-20161017 and COFEPRIS-17-CI-19-039-003), and registered at Clinicaltrials.gov (NCT03332888; Pre-Results).